Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate
- PMID: 21770925
- DOI: 10.1111/j.1528-1167.2011.03183.x
Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate
Abstract
Purpose: To compare the pharmacokinetics of USL255, a once-daily extended-release (ER) formulation of topiramate (TPM), with Topamax (immediate-release TPM) in healthy subjects after oral dosing and evaluate the effect of food on USL255 bioavailability and pharmacokinetics.
Methods: This randomized, single-center, open-label, cross-over design study had three dosing periods separated by 21 days of washout between treatments. Thirty-six volunteers received single doses of USL255 (200 mg) in fasted and fed conditions and two doses of Topamax (100 mg) administered 12 h apart. TPM plasma samples were analyzed by liquid chromatography-mass spectroscopy. Pharmacokinetic parameters were calculated by noncompartmental methods.
Key findings: USL255 fasted pharmacokinetic parameters [point estimate (90% confidence interval, CI) compared to Topamax] were: relative bioavailability (F) 91.2% (84-99%), peak plasma concentration (C(max)) USL255/Topamax-ratio 59% (53-65%), time to reach C(max) (t(max)) 19.5 ± 7.2 h, accumulation ratio (R(ac)) 3.9 ± 1.2, effective half-life (t(1/2,eff)) 55.7 ± 19.9 h, terminal half-life (t(1/2,z)) 80.2 ± 14.2 h, and peak-occupancy-time (POT) 12.1 ± 4.0 h. Although the F and C(max) were unaffected by food, R(ac) and t(1/2,eff) increased to 4.9 ± 0.9, and 72.5 ± 15.4 h, respectively. In contrast to t(1/2,z,) t(1/2,eff) reflects absorption rate; therefore, USL255's t(1/2,eff) was significantly longer than Topamax's t(1/2,eff) (37.1 ± 6.5 h).
Significance: Although bioequivalent to Topamax in extent of absorption, USL255 had a slower absorption rate as reflected in its lower C(max) and longer t(max), larger POT and longer t(1/2,eff), and similar R(ac) values to that of Topamax (q12 h). This relative flat plasma profile allows for once-daily dosing with diminished fluctuations in TPM plasma levels. In addition, neither USL255's peak nor extent of plasma exposure of TPM was affected by food.
Wiley Periodicals, Inc. © 2011 International League Against Epilepsy.
Similar articles
-
A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures.Ther Adv Neurol Disord. 2015 May;8(3):131-6. doi: 10.1177/1756285615578406. Ther Adv Neurol Disord. 2015. PMID: 25941540 Free PMC article. Review.
-
Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.Epilepsia. 2013 Aug;54(8):1444-52. doi: 10.1111/epi.12225. Epub 2013 May 20. Epilepsia. 2013. PMID: 23692553 Clinical Trial.
-
The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate.Epilepsy Res. 2017 Jan;129:26-32. doi: 10.1016/j.eplepsyres.2016.10.020. Epub 2016 Nov 9. Epilepsy Res. 2017. PMID: 27883934 Clinical Trial.
-
Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects.Curr Med Res Opin. 2010 Jun;26(6):1355-62. doi: 10.1185/03007991003740861. Curr Med Res Opin. 2010. PMID: 20377319 Clinical Trial.
-
USL255 extended-release topiramate for the treatment of epilepsy.Expert Rev Neurother. 2014 Oct;14(10):1127-37. doi: 10.1586/14737175.2014.958470. Epub 2014 Sep 13. Expert Rev Neurother. 2014. PMID: 25220748 Review.
Cited by
-
Topiramate Extended Release: A Review in Epilepsy.CNS Drugs. 2016 Jun;30(6):559-66. doi: 10.1007/s40263-016-0344-5. CNS Drugs. 2016. PMID: 27224993 Review.
-
Preparation and evaluation of bilayer-core osmotic pump tablets contained topiramate.PLoS One. 2022 Feb 25;17(2):e0264457. doi: 10.1371/journal.pone.0264457. eCollection 2022. PLoS One. 2022. PMID: 35213658 Free PMC article.
-
A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures.Ther Adv Neurol Disord. 2015 May;8(3):131-6. doi: 10.1177/1756285615578406. Ther Adv Neurol Disord. 2015. PMID: 25941540 Free PMC article. Review.
-
Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study.Epilepsia. 2014 Jul;55(7):1077-87. doi: 10.1111/epi.12660. Epub 2014 Jun 5. Epilepsia. 2014. PMID: 24902983 Free PMC article. Clinical Trial.
-
Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects.CNS Drugs. 2015 Aug;29(8):669-81. doi: 10.1007/s40263-015-0268-5. CNS Drugs. 2015. PMID: 26369919 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous